Veeva Systems and BioMarin Pharmaceutical announced a long‑term strategic partnership on January 8, 2026 that expands BioMarin’s use of Veeva’s industry‑cloud platform. The deal builds on a long‑standing relationship and is designed to accelerate the development and commercialization of BioMarin’s rare‑disease therapies by leveraging Veeva’s software, data, services, and consulting capabilities.
The partnership will deepen BioMarin’s use of Veeva’s core cloud offerings, including the Veeva Vault for content and data management, the Development Cloud for clinical trial operations, and the Commercial Cloud for market access and sales enablement. By integrating these solutions, BioMarin expects to shorten study timelines, improve data quality, and streamline regulatory submissions, thereby increasing the speed, agility, and operational efficiency of its drug‑development pipeline.
BioMarin’s pipeline spans central nervous system, cardiovascular, musculoskeletal/metabolic, and non‑oncology hematology areas, and the company has recently expanded its portfolio with the $4.8 billion acquisition of Amicus Therapeutics and the $270 million purchase of Inozyme Pharma. The partnership is positioned to support the commercialization of these new assets and to enhance the efficiency of ongoing programs, reinforcing BioMarin’s strategy to deliver transformative medicines to patients worldwide.
Veeva’s market share in the life‑sciences cloud platform sector was 16% in 2024, and the company’s platform is the leading choice for regulated industries. BioMarin’s market capitalization stands at $11.78 billion. Together, the alliance strengthens Veeva’s footprint in the biopharma market and reinforces BioMarin’s competitive moat by providing a scalable, integrated technology foundation.
“This strategic partnership marks an important next step in our digital evolution,” said Alexander Hardy, CEO of BioMarin. “Combining our scientific capabilities with Veeva’s technological leadership will enable us to bring transformative medicines more quickly to patients around the world.” Peter Gassner, Veeva’s CEO, added, “Building on a shared foundation of product excellence and customer success, we look forward to supporting BioMarin as they advance new medicines and reach more patients globally.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.